This launch strengthens USV’s presence in the Rs. 1,100 crore SGLT2i market and reinforces its leadership in oral anti-diabetes care. USV has introduced Xenia (empagliflozin 10 mg & 25 mg), Xenia M ...

empagliflozin is designed to improve glycaemic control in adults with T2DM, while also reducing cardiovascular outcomes in T2DM patients with CV risk and kidney diseases. India has an estimated 10.1 ...